{"filing":{"accession_number":"0001818794-26-000005","cik":"0001818794","ticker":"DYN","company_name":"Dyne Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"dyn-20260622.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818794/000181879426000005/dyn-20260622.htm"},"events":[{"id":12772,"run_id":11331,"accession_number":"0001818794-26-000005","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board elected Barry E. Greene as a Class I director on June 22, 2026. The disclosure centers on the appointment of a new director to the Board, including his compensation package (option grant of 57,463 shares at $20.87 and annual cash compensation of $45,000). This is a clear director appointment under Item 5.02, which is material to investors as it affects Board composition and governance.","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9721,"accession_number":"0001818794-26-000005","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board elected Barry E. Greene as a Class I director on June 22, 2026. The disclosure centers on the appointment of a new director to the Board, including his compensation package (option grant of 57,463 shares at $20.87 and annual cash compensation of $45,000). This is a clear director appointment under Item 5.02, which is material to investors as it affects Board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:51:35.533195+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9721,"accession_number":"0001818794-26-000005","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board elected Barry E. Greene as a Class I director on June 22, 2026. The disclosure centers on the appointment of a new director to the Board, including his compensation package (option grant of 57,463 shares at $20.87 and annual cash compensation of $45,000). This is a clear director appointment under Item 5.02, which is material to investors as it affects Board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:51:35.533195+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-22"}]}